Robert W. Baird Cuts Medtronic (NYSE:MDT) Price Target to $100.00

Medtronic (NYSE:MDT) had its target price decreased by Robert W. Baird from $103.00 to $100.00 in a research report released on Wednesday, Marketbeat Ratings reports. Robert W. Baird currently has a neutral rating on the medical technology company’s stock.

Several other analysts also recently issued reports on the stock. UBS Group reaffirmed a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a report on Wednesday, February 4th. Needham & Company LLC raised Medtronic from a “hold” rating to a “buy” rating and set a $121.00 target price on the stock in a research note on Monday, February 9th. Sanford C. Bernstein increased their target price on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Finally, Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $111.05.

Medtronic Stock Down 0.7%

MDT opened at $96.88 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a market cap of $124.20 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 2.45 and a beta of 0.71. Medtronic has a one year low of $79.55 and a one year high of $106.33. The business’s fifty day moving average is $99.04 and its two-hundred day moving average is $96.65.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the previous year, the company posted $1.38 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts anticipate that Medtronic will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s dividend payout ratio is 79.11%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MDT. Corundum Trust Company INC acquired a new position in Medtronic during the third quarter worth approximately $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic in the 4th quarter valued at $27,000. Anfield Capital Management LLC grew its stake in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Medtronic during the 4th quarter valued at $29,000. Finally, GoalVest Advisory LLC acquired a new stake in shares of Medtronic during the 4th quarter worth $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).